References
- Anwar WA, Khaled HM, Amra HA, et al (2008). Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res, 659, 176-84. https://doi.org/10.1016/j.mrrev.2008.01.005
- Borel F, Konstantinova P, Jansen PL (2012). Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol, 56, 1371-83.
- Bushati N, Cohen SM (2007). microRNA functions. Annu Rev Cell Dev Biol, 23, 175-205. https://doi.org/10.1146/annurev.cellbio.23.090506.123406
- Chen DS, Sung JL, Sheu JC, et al (1984). Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterol, 86, 1404-9.
- Chen XM (2009). MicroRNA signatures in liver diseases. World J Gastroenterol, 15, 1665-72. https://doi.org/10.3748/wjg.15.1665
- Chen X, Zhang L, Zhang T, et al (2013). Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int, 33, 476-86. https://doi.org/10.1111/liv.12097
- El-Abd NE, Fawzy NA, El-Sheikh SM, et al (2015). Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in egyptian patients with chronic hepatitis C virus infection. Mol Diagn Ther, 19, 213-20. https://doi.org/10.1007/s40291-015-0148-1
- Fesler A, Zhai H, Ju J (2014). miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer. Onco Targets Ther, 21, 1481-5.
- Fukao T, Fukuda Y, Kiga K, et al (2007). An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell, 129, 617-31. https://doi.org/10.1016/j.cell.2007.02.048
- Furuta M, Kozaki KI, Tanaka S, et al (2010). miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 31, 766-76. https://doi.org/10.1093/carcin/bgp250
- Han ZB, Chen HY, Fan JW, et al (2012). Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol, 138, 153-61. https://doi.org/10.1007/s00432-011-1076-z
- Huang S, He X (2011). The role of microRNAs in liver cancer progression. Br J Cancer, 104, 235-40. https://doi.org/10.1038/sj.bjc.6606010
- Hung CH, Chiu YC, Chen CH, et al (2014). MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int, 2014, 486407.
- Johnnidis JB, Harris MH, Wheeler RT, et al (2008). Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature, 451, 1125-9. https://doi.org/10.1038/nature06607
- Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17 https://doi.org/10.1016/S0140-6736(03)14964-1
- Liu Y, Ren F, Rong M, et al (2015). Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int, 15, 62. https://doi.org/10.1186/s12935-015-0214-0
- Lu CY, Lin KY, Tien MT, et al (2013). Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma. Genes Chromosomes Cancer, 52, 636-43.
- Marrero JA, Lok AS (2004). Newer markers for hepatocellular carcinoma. Gastroenterol, 127, 113-9. https://doi.org/10.1053/j.gastro.2004.09.024
- Okuda H, Nakanishi T, Takatsu K, et al (2000). Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer, 88, 544-9. https://doi.org/10.1002/(SICI)1097-0142(20000201)88:3<544::AID-CNCR8>3.0.CO;2-F
- Omar A, Abou-Alfa GK, Khairy A, et al (2013). Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol, 2, 43.
- Tateishi R, Yoshida H, Matsuyama Y, et al (2008). Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int, 2, 17-30 https://doi.org/10.1007/s12072-007-9038-x
- Wan D, Shen S, Fu S, et al (2015). miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC. Anticancer Agents Med Chem. Details?
- Wei W, Wanjun L, Hui S, et al (2013). miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct, 31, 82-5. https://doi.org/10.1002/cbf.2863
- Wong QW, Lung RW, Law PT, et al (2008). MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterol, 135, 257-69. https://doi.org/10.1053/j.gastro.2008.04.003
- Xu J, Wu C, Che X, et al (2011). Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 50, 136-42. https://doi.org/10.1002/mc.20712
- Yu CH, Xu CF, Li YM (2009). Association of microRNA-223 expression with hepatic ischemia/reperfusion injury in mice. Dig Dis Sci, 54, 2362-6. https://doi.org/10.1007/s10620-008-0629-8
- Zhang Y, Wei W, Cheng N, et al (2012). Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating wnt signaling. Hepatol, 56, 1631-40. https://doi.org/10.1002/hep.25849